SMARCB1

Across TCGA pan-cancer cohorts, SMARCB1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMARCB1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SMARCB1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SMARCB1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where SMARCB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	III,IV	0.688	0.968	.001	51	view →
PDAC	OS	Median	III,IV	1.000	0.537	.008	11	view →
LSCC	DFS	Median	All	0.972	0.906	.006	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.842	1.000	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMARCB1–HNSC (OS)

Open the HNSC breakdown →